Epidemiology and risk factors for gram-positive coccal infections in neutropenia: Toward a more targeted antibiotic strategy

Clinical Infectious Diseases

Volumn 36, Issue 2, 2003, Pages 149-158

  Cordonnier, Catherine ^a   Buzyn, Agnès ^b   Leverger, Guy ^c   Herbrecht, Raoul ^d   Hunault, Mathilde ^e   Leclercq, Roland ^e   Bastuji Garin, Sylvie ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYTARABINE; GLYCOPEPTIDE; NEOMYCIN; PROTON PUMP INHIBITOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CHILL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTESTINE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; RISK FACTOR; SCORING SYSTEM; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; FEVER; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; NEUTROPENIA; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; STREPTOCOCCAL INFECTIONS;

EID: 0037439502     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/345435     Document Type: Article

References (36)

1. Kern W, Kurrle E, Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy: a review of 55 cases. Infection 1990; 18:138-45.
2. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14:1201-7.
3. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994; 97:256-64.
4. Jones R. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29:495-502.
5. Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247-59.
6. Hugues WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25:551-73.
7. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 1999; 29:503-7.
8. Engelhard D, Elishoov A, Strauss N, et al. Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. Transplantation 1996; 61:430-4.
9. Viscoli C, Castagnola E, Giacchino M, et al. Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology. Supportive Therapy Group-Infectious Diseases Section. Eur J Cancer 1999; 35:770-4.
10. Madani T. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection 2000; 28:367-73.
11. Ninin E, Milpied N, Moreau P, et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis 2001; 33:41-7.
12. Reed EC. Infectious complications during autotransplantation. Hematol Oncol Clin North Am 1993; 7:717-35.
13. Bochud PY, Eggiman T, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans Streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18:25-31.
14. Hughes WT, Armstrong DA, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161:381-96.
15. Soussy C, Cluzel R, Courvalin P. Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. Eur J Clin Microbiol Infect Dis 1994; 13:238-46.
16. Breslow NE, Day NA, eds. Statistical methods in cancer research. Vol I. The analysis of case-control studies. International Agency for Research on Cancer (IARC) scientific publication no. 32. Lyon, France: IARC, 1980.
17. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982; 115:92-106.
18. Hanley J, McNeil B. The meaning and use of the area under a receiver operating characteristic ROC curve. Radiology 1982; 143:29-36.
19. Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33:1295-301.
20. Cordonnier C, Pico JL, Gardembas M, et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 1997; 24:41-51.
21. Cometta A, Zinner S, De Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39:445-52.
22. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163:951-8.
23. Ramphal R, Bolger M, Oblon D, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992; 36:1062-7.
24. Cohen J, Donnely JP, Worsley AM, et al. Septicemia caused by viridans streptococci in neutropenic patients with leukemia. Lancet 1983; 2:1452-4.
25. Henslee J, Bostrom B, Weisdorf D, et al. Streptococcal sepsis in bone marrow transplant patient. Lancet 1984; 1:393.
26. Villablanca JG, Steiner M, Kersey J, et al. The clinical spectrum of infections with viridans streptococci in bone marrow transplant. Bone Marrow Transplant 1990; 5:387-93.
27. Engelhard D, Elishoov H, Or R, et al. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant 1995; 16:565-70.
28. Engels EA, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16:1179-87.
29. Claessen DC, Burke JP, Ford CD, et al. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 1990; 89:441-6.
30. Viscoli C, Paesmens M, Sanz M, et al. Association between antifungal prophylaxis and rate of documented bacteremia, in febrile neutropenic cancer patients. Clin Infect Dis 2001; 32:1532-7.
31. Gosse C, Faure E, Ardouin P, Andremont A, Tancrede C. Experimental intestinal microflora in mice with a changeable population size of E. coli. Prog Clin Biol Res 1985; 181:175-7.
32. Palmblad J, Lonnqvist B, Carlsson B, et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukemia in adults: more bacteremias. J Intern Med 1992; 231:363-70.
33. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasia. J Infect Dis 1995; 172:1035-41.
34. Kern W, Behre G, Rudolf T, et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia. Cancer 1998; 83:291-301.
35. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind multicenter trial. Clin Infect Dis 1999; 28:250-5.
36. Martino P, Micozzi A, Gentile G, Raccah R, Girmenia C, Mandelli F. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. Clin Infect Dis 1992; 15:290-4.